secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition Corp. (DMAA)
CIK:        0002028614
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001213900-26-051018
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SPAC DMAA shareholders approve extension to April 2027; ~28% of shares redeemed for $99.3M
--------------------------------------------------------------------------------

- Extension proposal approved: 18,906,281 for, 4,892,646 against, 0 abstain.
- Combination period extended up to 12 months to April 29, 2027 with monthly deposits of ~$300k.
- Redemption of 9,440,230 shares at ~$10.52/share, removing $99,336,016.67 from trust account.
- Post-redemption shares outstanding: 24,276,913 (13,559,770 from IPO).
- Board approved initial one-month extension to May 29, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/0001213900-26-051018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/ea0288774-8k_drugs.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-051018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer